Cargando…
Implications of Heterogeneity in Multiple Myeloma
Multiple myeloma is the second most common hematologic malignancy in the world. Despite improvement in outcome, the disease is still incurable for most patients. However, not all myeloma are the same. With the same treatment, some patients can have very long survival whereas others can have very sho...
Autores principales: | de Mel, Sanjay, Lim, Su Hong, Tung, Moon Ley, Chng, Wee-Joo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102035/ https://www.ncbi.nlm.nih.gov/pubmed/25101266 http://dx.doi.org/10.1155/2014/232546 |
Ejemplares similares
-
Immunotherapy in Multiple Myeloma
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2020) -
STAT3: A Promising Therapeutic Target in Multiple Myeloma
por: Chong, Phyllis S. Y., et al.
Publicado: (2019) -
Potential Clinical Application of Genomics in Multiple Myeloma
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2018) -
Tumor-Associated Macrophages and Related Myelomonocytic Cells in the Tumor Microenvironment of Multiple Myeloma
por: Wang, Samuel S. Y., et al.
Publicado: (2022) -
Metabolic Vulnerabilities in Multiple Myeloma
por: Lim, Julia S. L., et al.
Publicado: (2022)